Matrix metalloproteinases genes polymorphism in the development of new cardiovascular events

Dana Taizhanova 1, Akerke Kalimbetova 1 * , Ainur Akilzhanova 2
More Detail
1 No1 Department of Internal Diseases, Karaganda Medical University, Karaganda city, Republic of Kazakhstan
2 Laboratory of Genomic and Personalized Medicine, National Laboratory Astana, Nazarbayev University, Nur-Sultan city, Republic of Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 4, Issue 58, pp. 19-22. https://doi.org/10.23950/1812-2892-JCMK-00778
OPEN ACCESS 1938 Views 1755 Downloads
Download Full Text (PDF)

ABSTRACT

The review article presents a study of the literature on the relationship of gene polymorphism of matrix metalloproteinases (MMP 2 (−1575 G>A), MMP3 (−1171 5A/6A), MMP 9 (−1562 C/T) with the risk of developing new cardiovascular events after percutaneous coronary intervention. To achieve this goal, a systematic search and subsequent analysis of publications and online resources was carried out. All publications are indexed in Scopus, Web of Knowledge and e-library.
Keywords: coronary heart disease, percutaneous coronary intervention, (MMP 2 (−1575 G>, A), MMP3 (−1171 5A/6A), MMP 9 (−1562 C/T), new cardiovascular events, stenting

CITATION

Taizhanova D, Kalimbetova A, Akilzhanova A. Matrix metalloproteinases genes polymorphism in the development of new cardiovascular events. Journal of Clinical Medicine of Kazakhstan. 2020;4(58):19-22. https://doi.org/10.23950/1812-2892-JCMK-00778

REFERENCES

  • T. Klein, R. Bischoff. Physiology and pathophysiology of matrix metalloproteinases. Amino Acids. 2011; 41:271-290. https://doi.org/10.1007/s00726-010-0689-x
  • Alp E., Menevse S., Tulmac M. et al. The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet Test Mol Biomarkers. 2011; 15(4):193-202. https://doi.org/10.1089/gtmb.2010.0113
  • Kaplan RC, Smith NL, Zucker S, et al. Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis. 2008; 201:130-137. https://doi.org/10.1016/j.atherosclerosis.2008.01.003
  • S. Abilleira, S. Bevan, H.S. Markus The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J. Med. Genet. 2006ж 43:897-901. https://doi.org/10.1136/jmg.2006.040808
  • Mancia G, Fagard R, Narkiewicz K, et al. The 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. European heart journal. 2013; 2159-219. https://doi.org/10.1093/eurheartj/eht151
  • Zhou S, Feely J, Spiers J, et al. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens. 2007; 21:861-7. https://doi.org/10.1038/sj.jhh.1002244
  • Panchenko EA, Nevzorova VA, Belov PS, et al. Polymorphism of matrix metalloproteinases 2 and 9 genes in patients with myocardial infarction combined with metabolic syndrome. Fundamental research. 2014; 10:1964-70.
  • Li J, Lu H, Tao F, et al. Meta-analysis of MMP9-562C/T and the risk of coronary heart disease. Cardiology. 2013; 124(1):53-9. https://doi.org/10.1159/000345772
  • Lin RT, Chen CH, Tsai PC, et al. Sex-specific effect of matrix Metalloproteinase-9 functional promoter polymorphism on carotid artery stiffness. J Atherosclerosis. 2012; 416-20. https://doi.org/10.1016/j.atherosclerosis.2012.05.031
  • Huang R, Deng L, Shen AN, et al. Associations of MMP1, 3, 9 and TIMP3 Genes Polymorphism with Isolated Systolic Hypertension in Chinese Han Population. International J Med Scie. 2013; 10(7): 840-7. https://doi.org/10.7150/ijms.5728
  • Yadav SS, Mandal RK, Singh MK, et al. High serum level of matrix metalloproteinase 9 and promoter polymorphism - 1562 C:T as a new risk factor for metabolic syndrome. DNA Cell Biol. 2014; 33(11): 816-22. https://doi.org/10.1089/dna.2014.2511
  • Lacchini R, Jacob-Ferreira AL, Luizon MR, et al. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Human Hypertension. 2012; 26: 171-7. https://doi.org/10.1038/jhh.2011.8
  • da Fonseca, A.L.M., Oliveira, R.J.B., Santos, J.C.A., Cardoso, L.S., Couto, F.D. et all. Matrix metalloproteinases 2 and 9 are CAD more relevant biomarkers than-1,-8, and-12 to separate CAD from non-CAD patients. Open Biomarkers Journal. 2019; 9(1):22-30. https://doi.org/10.2174/1875318301909010022
  • Koch W, de Waha A, Hoppmann P, et al. Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta analysis. Atherosclerosis. 2010; 208:171-176. https://doi.org/10.1016/j.atherosclerosis.2009.08.021 
  • Zhang F.X., Sun D.P., Guan N. et al. Association between -1562C>T polymorphism in the promoter region of matrix metalloproteinase-9 and coronary artery disease: a meta-analysis. Genet Test Mol Biomarkers. 2014; 18(2):98-105. https://doi.org/10.1089/gtmb.2013.0369
  • Opstad TB, Pettersen AÅ, Arnesen H, et al. The co-existence of the IL-18 +183 A/G and MMP-9 -1562C/T polymorphisms is associated with clinical events in coronary artery disease patients. PLoS ONE. 2013; 8: e74498. https://doi.org/10.1371/journal.pone.0074498
  • Padang R, Bannon P, Jeremy R, et al. The genetic and molecular basis of bicuspid aortic valve associated thoracic aortopathy: a link to phenotype heterogenecity. Ann Cardiothorac Surg. 2013; 2(1):83-91.
  • Fedak P, de Sa M, Verma S, et al. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Catdiovasc Surg. 2003; 126:797-806. https://doi.org/10.1016/S0022-5223(03)00398-2
  • Boyum J, Fellinger E, Schmoker J, et al. Matrix metalloproteinase activity in thoracic aortic aneurisms associated with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc.Surg. 2004; 127: 686-91. https://doi.org/10.1016/j.jtcvs.2003.11.049
  • Loscalzo M, Goh D, Loeys B, et al. Familial thoracic aortic dilatation and bicomissural aortic valve: a prospective analysis of natural history and inheritance. Am J Med Genet A. 2007; 143A: 1960-7. https://doi.org/10.1002/ajmg.a.31872
  • OMIM (On-line Mendelian Inheritance in Man) www.ncbi.nlm.nih.gov/omim.
  • Guizani, I., Zidi, W., Zayani, Y., Boudiche, S., Hadj-Taieb et all. Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5 years cohort study. 2019; Molecular Biology Reports. 46(5):4699-4707. https://doi.org/10.1007/s11033-019-04914-4
  • Liu PY, Chen JH, Li YH, et al. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost. 2003; 90:132-139. https://doi.org/10.1055/s-0037-1613609
  • Niu W., Qi Y. Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: systematic review and metaanalysis. Heart. 2012; 98(20):1483-1491. https://doi.org/10.1136/heartjnl-2012-302085
  • Xin Xu, Lihan Wang, Changfu Xu, Peng Zhang, Fendi Yong et all. Variations in matrix metalloproteinase-1, -3, and -9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coronary Artery Disease. 2013; 24(4):259-265. https://doi.org/10.1097/MCA.0b013e32835ea3af
  • Nojiri T, Morita H, Imai Y, et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol. 2003; 92:181-186. https://doi.org/10.1016/S0167-5273(03)00100-1
  • Niu W., Qi Y. Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: systematic review and metaanalysis. Heart. 2012; 98(20):1483-1491. https://doi.org/10.1136/heartjnl-2012-302085
  • Humphries S, Bauters C, Meirhaeghe A et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP 3) gene as a risk factor for restenosis. Eur. Heart J. 2002; 23(9):721-725. https://doi.org/10.1053/euhj.2001.2895
  • Hoppmann P, Koch W et al. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur Heart J. 2004; 25(4):335-41. https://doi.org/10.1016/j.ehj.2003.12.004
  • Blankenberg, S., Rupprecht, H.J., Poirier, O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107(12):1579-1585. https://doi.org/10.1161/01.CIR.0000058700.41738.12
  • Lacchini, R., Metzger, I.F., Luizon, M., et al., 2010. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol. 29(11):649-655. https://doi.org/10.1089/dna.2010.1056
  • Metzger, et al. Genetic Variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects. DNA Cell Biol. 2012; 31(4):504-510. https://doi.org/10.1089/dna.2011.1388
  • Juan, Z., Wei-Guo, Z., Heng-Liang, S., Da-Guo, W.Association of matrix metalloproteinase 9 C-1562T polymorphism with genetic susceptibility to myocardial infarction: A meta-analysis. Current Therapeutic Research - Clinical and Experimental. 2015; 77:40-45. https://doi.org/10.1016/j.curtheres.2014.05.001
  • Wang, X., Shi, L.-Z. Association of matrix metalloproteinase-9 C1562T polymorphism and coronary artery disease: A meta-analysis. Journal of Zhejiang University: Science B. 2014; 15(3):256-263. https://doi.org/10.1631/jzus.B1300088